Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

This study is not yet open for participant recruitment.

Verified by Hadassah Medical Organization, September 2007

First Received: September 19, 2007 No Changes Posted

Sponsor:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00532519

Purpose

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.

Condition	Intervention
Prurigo Nodularis	Drug: citalopram (cipralex)

Study Type:	Interventional
Study Design:	Open Label, Single Group Assignment

Resource links provided by NLM:

Drug Information available for: Serotonin Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Intervention Details:

10-20 mg/day, for 12 weeks.

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

prurigo nodularis
age: 18-70 years
agreed to participate

Exclusion Criteria:

younger than 18 or older than 70
pregnant or lactating women
chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
sensitivity to cipralotam
psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532519

Contacts

Contact: Liran Horev, MD

OO97226777111

LIRAN_CH@BEZEQINT.NET

Locations

Israel
: Hadassah Medical Organization,
Jerusalem, Israel

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:	liran horev, md	Hadassah Medical Organization, Jerusalem, Israel
Principal Investigator:	rena cooper-kazaz, md	Hadassah-Hebrew University Medical Center

More Information

No publications provided

Study ID Numbers:	horcoop-hmo-ctil
Study First Received:	September 19, 2007
Last Updated:	September 19, 2007
ClinicalTrials.gov Identifier:	NCT00532519 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:

Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Cholinergic Agents
Prurigo
Therapeutic Uses
Skin Diseases, Eczematous
Antidepressive Agents, Second-Generation

Dexetimide
Antidepressive Agents
Dermatitis
Skin Diseases
Serotonin Uptake Inhibitors
Citalopram
Pharmacologic Actions
Muscarinic Antagonists
Serotonin Agents
Autonomic Agents
Peripheral Nervous System Agents
Neurodermatitis
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 30, 2009